Cybin Inc. (Cybin), a biopharmaceutical company, has announced the completion of a private placement offering of common shares, raising gross proceeds of up to $150 million. The offering was conducted on a 'commercially reasonable efforts' basis by Bloom Burton Securities Inc. (Lead Agent) and Haywood Securities Inc. (collectively, the 'Agents'). The shares were priced at $0.43 each, with the event dated March 19, 2024. The offering was made to purchasers in Canada, the United States, and offshore jurisdictions, exempt from registration requirements under U.S. securities laws. The Agents were entitled to an offering fee of 6.0% of the aggregate gross proceeds, reduced to 3.0% for president's list purchasers introduced by Cybin. The offering aimed to issue and sell common shares without underwriter liability, with the Agents appointing other dealers to assist in the offering. The Agents were responsible for their remuneration, payable from their offering fee. The offering's completion was subject to customary closing conditions, including regulatory approvals and the execution of subscription agreements with purchasers.

Cybin Inc. (Cybin), a biopharmaceutical company, has announced the completion of a private placement offering of common shares, raising gross proceeds of up to $150 million. The offering was conducted on a 'commercially reasonable efforts' basis by Bloom Burton Securities Inc. (Lead Agent) and Haywood Securities Inc. (collectively, the 'Agents'). The shares were priced at $0.43 each, with the event dated March 19, 2024. The offering was made to purchasers in Canada, the United States, and offshore jurisdictions, exempt from registration requirements under U.S. securities laws. The Agents were entitled to an offering fee of 6.0% of the aggregate gross proceeds, reduced to 3.0% for president's list purchasers introduced by Cybin. The offering aimed to issue and sell common shares without underwriter liability, with the Agents appointing other dealers to assist in the offering. The Agents were responsible for their remuneration, payable from their offering fee. The offering's completion was subject to customary closing conditions, including regulatory approvals and the execution of subscription agreements with purchasers.